Experience with Vildagliptin in Patients ≥75 Years with Type 2 Diabetes and Moderate or Severe Renal Impairment
Open Access
- 3 July 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 4 (2), 257-267
- https://doi.org/10.1007/s13300-013-0027-x
Abstract
Patients with type 2 diabetes (T2DM) are at increased risk for renal impairment (RI) and, in addition, there is an age-related decline in renal function. At the same time, T2DM treatment is more complex and treatment options are more limited in elderly patients as well as patients with RI, with the patient population ≥75 years with moderate or severe RI posing unique challenges, in particular, the high risk and more severe consequences of hypoglycemia. It was, therefore, of interest to assess the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor vildagliptin in patients with T2DM ≥75 years who also have moderate or severe RI.This publication has 28 references indexed in Scilit:
- Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulinVascular Health and Risk Management, 2013
- Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairmentVascular Health and Risk Management, 2013
- Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trialDiabetes, Obesity and Metabolism, 2011
- Mechanisms of action of the dipeptidyl peptidase-4 inhibitor vildagliptin in humansDiabetes, Obesity and Metabolism, 2011
- Minimizing the risk of hypoglycemia with vildagliptin: Clinical experience, mechanistic basis, and importance in type 2 diabetes managementDiabetes Therapy, 2011
- Assessing the general safety and tolerability of vildagliptin: value of pooled analyses from a large safety database versus evaluation of individual studiesVascular Health and Risk Management, 2011
- Weight neutrality with the DPP-4 inhibitor, vildagliptin: Mechanistic basis and clinical experienceVascular Health and Risk Management, 2010
- Hypoglycemia Unawareness in Older Compared With Middle-Aged Patients With Type 2 DiabetesDiabetes Care, 2009
- Frequency of Hypoglycemia and Its Significance in Chronic Kidney DiseaseClinical Journal of the American Society of Nephrology, 2009
- Hypoglycaemia in Elderly Patients with Diabetes MellitusDrugs & Aging, 2004